# Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers

> **NIH NIH U01** · UNIVERSITY OF FLORIDA · 2020 · $212,696

## Abstract

The objective of this University of Florida/Advent Health proposal within the Type 1 Diabetes in Acute
Pancreatitis Consortium (T1DAPC) is to establish a longitudinal prospective cohort of patients with acute and
acute relapsing pancreatitis in order to investigate the incidence, pathophysiology, mechanisms, environmental
and biologic risk factors, and predictors of subsequent diabetes. The Diabetes Institute at UF (UFDI) and the
Advent Health Translational Research Institute have the resources and capabilities required to perform
comprehensive genetic, immunologic, metabolic, histologic, and functional testing to dissect the various
mechanisms underlying diabetes following acute pancreatitis. Our proposal addresses four key needs of the
T1DAPC. 1) A platform for recruiting large numbers of subjects with acute or acute relapsing pancreatitis. The
combined volumes of both health systems approach 2,000 patients admitted with acute pancreatitis yearly.
The clinical expertise and existing clinical research support structure is experienced and capable, and the two
Institutes have the scientific expertise to help define and support the whole variety of mechanistic studies that
will be undertaken; 2) Mechanistic studies of diabetes after acute pancreatitis including a) measuring
autoantibody markers of islet autoimmunity after acute pancreatitis (subaim 1a); b) assessing subjects’ type 1
diabetes genetic risk leveraging a custom genotyping array and log additive genetic risk score (subaim 1b);
comprehensively characterizing 𝛽𝛽-cell function after acute pancreatitis (subaim 1c); and d) analyzing the
imaging features of acute pancreatitis which predict the subsequent development of diabetes (subaim 1d); 3) A
consortium opportunity to study human subjects prior to the development of acute pancreatitis, that occurring
after endoscopic retrograde cholangiopancreatography (ERCP). UFHealth and AdventHealth perform
approximately 2,400 of these procedures yearly, and with the participation of other T1DAPC centers, a sub-
cohort could be assembled with biospecimens and imaging data prior to the development of acute pancreatitis,
providing a very useful comparison population for future analyses. 4) Collecting a bank of human pancreata
from subjects with previous pancreatitis. The Network for Pancreatic Organ donors with Diabetes (nPOD),
housed at the UFID, collects and processes transplant-grade pancreata and other tissues from organ
procurement organizations (OPOs) across the U.S. and provides them for investigators around the world. We
will leverage this infrastructure, along with that of a large local OPO associated with AdventHealth, to obtain
organs from individuals with a history of acute pancreatitis. This will provide a unique resource for the
T1DAPC, to interrogate the mechanisms of diabetes in tissue, which is not readily accessible in living subjects.
This can provide a clinicopathologic correlation for the T1DAPC mechanistic studies. We believe the typ...

## Key facts

- **NIH application ID:** 10127734
- **Project number:** 1U01DK127392-01
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **Principal Investigator:** CHRISTOPHER E FORSMARK
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $212,696
- **Award type:** 1
- **Project period:** 2020-09-16 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10127734

## Citation

> US National Institutes of Health, RePORTER application 10127734, Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (1U01DK127392-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10127734. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*